Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Drops By 93.8%

Xenetic Biosciences Inc (NASDAQ:XBIO) was the recipient of a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 500 shares, a decline of 93.8% from the November 30th total of 8,100 shares. Based on an average trading volume of 24,400 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the company’s shares are sold short.

Xenetic Biosciences Trading Up 1.7 %

NASDAQ:XBIO opened at $4.11 on Friday. Xenetic Biosciences has a 12 month low of $2.78 and a 12 month high of $5.20. The company has a 50-day moving average price of $4.03 and a 200-day moving average price of $3.98. The stock has a market cap of $6.34 million, a price-to-earnings ratio of -1.55 and a beta of 2.24.

Xenetic Biosciences (NASDAQ:XBIO) last released its earnings results on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14). The firm had revenue of $0.61 million during the quarter, compared to analysts’ expectations of $0.75 million. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. Equities analysts forecast that Xenetic Biosciences will post -1.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “neutral” rating on shares of Xenetic Biosciences in a report on Thursday, December 5th.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.